495 related articles for article (PubMed ID: 19628936)
1. Current management and risk of recurrent stroke in cerebrovascular patients with right-to-left cardiac shunt.
Weimar C; Holle DN; Benemann J; Schmid E; Schminke U; Haberl RL; Diener HC; Goertler M;
Cerebrovasc Dis; 2009; 28(4):349-56. PubMed ID: 19628936
[TBL] [Abstract][Full Text] [Related]
2. Outcome after percutaneous closure of a patent foramen ovale using the Intrasept device: a multi-centre study.
Luermans JG; Post MC; Schräder R; Sluysmans T; Vydt T; Vermeersch P; Chessa M; Onorato E; Goy JJ; Budts WI
Catheter Cardiovasc Interv; 2008 May; 71(6):822-8. PubMed ID: 18324695
[TBL] [Abstract][Full Text] [Related]
3. Causes of recurrent focal neurologic events after transcatheter closure of patent foramen ovale with the CardioSEAL septal occluder.
Kutty S; Brown K; Asnes JD; Rhodes JF; Latson LA
Am J Cardiol; 2008 May; 101(10):1487-92. PubMed ID: 18471463
[TBL] [Abstract][Full Text] [Related]
4. Prognosis after cryptogenic cerebral ischemia in patients with coagulopathies.
Weber R; Goertler M; Benemann J; Diener HC; Weimar C;
Cerebrovasc Dis; 2009; 28(6):611-7. PubMed ID: 19851066
[TBL] [Abstract][Full Text] [Related]
5. Patent foramen ovale closure following cryptogenic stroke or transient ischaemic attack: Long-term follow-up of 301 cases.
Mirzaali M; Dooley M; Wynne D; Cooter N; Lee L; Haworth P; Saha R; Gainsborough N; Hildick-Smith D
Catheter Cardiovasc Interv; 2015 Nov; 86(6):1078-84. PubMed ID: 26105198
[TBL] [Abstract][Full Text] [Related]
6. Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study.
Paciaroni M; Agnelli G; Bertolini A; Pezzini A; Padovani A; Caso V; Venti M; Alberti A; Palmiero RA; Cerrato P; Silvestrelli G; Lanari A; Previdi P; Corea F; Balducci A; Ferri R; Falcinelli F; Filippucci E; Chiocchi P; Grandi FC; Ferigo L; Musolino R; Bersano A; Ghione I; Sacco S; Carolei A; Baldi A; Ageno W;
Cerebrovasc Dis; 2011; 31(2):109-16. PubMed ID: 21088390
[TBL] [Abstract][Full Text] [Related]
7. Percutaneous closure of patent foramen ovale in cryptogenic embolism.
Meier B; Kalesan B; Mattle HP; Khattab AA; Hildick-Smith D; Dudek D; Andersen G; Ibrahim R; Schuler G; Walton AS; Wahl A; Windecker S; Jüni P;
N Engl J Med; 2013 Mar; 368(12):1083-91. PubMed ID: 23514285
[TBL] [Abstract][Full Text] [Related]
8. Outcomes after transcatheter closure of patent foramen ovale in patients with paradoxical embolism.
Harms V; Reisman M; Fuller CJ; Spencer MP; Olsen JV; Krabill KA; Gray WA; Jesurum JT
Am J Cardiol; 2007 May; 99(9):1312-5. PubMed ID: 17478164
[TBL] [Abstract][Full Text] [Related]
9. Long-term propensity score-matched comparison of percutaneous closure of patent foramen ovale with medical treatment after paradoxical embolism.
Wahl A; Jüni P; Mono ML; Kalesan B; Praz F; Geister L; Räber L; Nedeltchev K; Mattle HP; Windecker S; Meier B
Circulation; 2012 Feb; 125(6):803-12. PubMed ID: 22238228
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of transcatheter patent foramen ovale closure in migraineurs with moderate to large right-to-left shunt and instrumental evidence of cerebrovascular damage.
Papa M; Gaspardone A; Fragasso G; Ajello S; Gioffrè G; Iamele M; Iani C; Margonato A
Am J Cardiol; 2009 Aug; 104(3):434-9. PubMed ID: 19616680
[TBL] [Abstract][Full Text] [Related]
11. Percutaneous closure of patent foramen ovale with a bioabsorbable occluder device: single-centre experience.
Ussia GP; Cammalleri V; Mulè M; Scarabelli M; Barbanti M; Scardaci F; Mangiafico S; Immè S; Capodanno D; Tamburino C
Catheter Cardiovasc Interv; 2009 Oct; 74(4):607-14. PubMed ID: 19360875
[TBL] [Abstract][Full Text] [Related]
12. Percutaneous device closure of patent foramen ovale in patients with presumed cryptogenic stroke or transient ischemic attack: the Mayo Clinic experience.
Ford MA; Reeder GS; Lennon RJ; Brown RD; Petty GW; Cabalka AK; Cetta F; Hagler DJ
JACC Cardiovasc Interv; 2009 May; 2(5):404-11. PubMed ID: 19463462
[TBL] [Abstract][Full Text] [Related]
13. Major vascular events after transient ischaemic attack and minor ischaemic stroke: post hoc modelling of incidence dynamics.
Atanassova PA; Chalakova NT; Dimitrov BD
Cerebrovasc Dis; 2008; 25(3):225-33. PubMed ID: 18216464
[TBL] [Abstract][Full Text] [Related]
14. Percutaneous closure of patent foramen ovale in patients with presumed paradoxical embolism: periprocedural results and midterm risk of recurrent neurologic events.
Balbi M; Casalino L; Gnecco G; Bezante GP; Pongiglione G; Marasini M; Del Sette M; Barsotti A
Am Heart J; 2008 Aug; 156(2):356-60. PubMed ID: 18657668
[TBL] [Abstract][Full Text] [Related]
15. Management and outcome of patients with transient ischemic attack admitted to a stroke unit.
Calvet D; Lamy C; Touzé E; Oppenheim C; Meder JF; Mas JL
Cerebrovasc Dis; 2007; 24(1):80-5. PubMed ID: 17519548
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous large right-to-left shunt and migraine headache with aura are risk factors for recurrent stroke in patients with a patent foramen ovale.
Giardini A; Donti A; Formigari R; Salomone L; Palareti G; Guidetti D; Picchio FM
Int J Cardiol; 2007 Sep; 120(3):357-62. PubMed ID: 17166607
[TBL] [Abstract][Full Text] [Related]
17. Secondary prevention after cryptogenic cerebrovascular events in patients with patent foramen ovale.
Schuchlenz HW; Weihs W; Berghold A; Lechner A; Schmidt R
Int J Cardiol; 2005 May; 101(1):77-82. PubMed ID: 15860387
[TBL] [Abstract][Full Text] [Related]
18. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke.
Carroll JD; Saver JL; Thaler DE; Smalling RW; Berry S; MacDonald LA; Marks DS; Tirschwell DL;
N Engl J Med; 2013 Mar; 368(12):1092-100. PubMed ID: 23514286
[TBL] [Abstract][Full Text] [Related]
19. [Percutaneous closure of patent foramen ovale, as secondary prevention of cryptogenic cerebral event].
Temesvári A; Bálint OH; Liptai C; Kancz S; Németh B; Szatmári A
Orv Hetil; 2006 Oct; 147(42):2035-9. PubMed ID: 17165604
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.
Smith EE; Cannon CP; Murphy S; Feske SK; Schwamm LH
Am Heart J; 2006 Feb; 151(2):338-44. PubMed ID: 16442896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
